Core Viewpoint - Biotechnology company Baoyi Pharmaceutical-B (02659) has successfully completed its subscription period from December 2 to 5, with expectations to list on December 10, indicating strong market interest and demand for its shares [1] Group 1: Subscription and Oversubscription - Baoyi Pharmaceutical has secured HKD 269.21 billion in margin financing from brokers, significantly exceeding its public offering amount of HKD 100 million, resulting in an oversubscription rate of 2,690.8 times [1] - The company plans to issue 37.912 million H-shares, with 10% allocated for public offering at a price of HKD 26.38 per share, aiming to raise HKD 100 million [1] Group 2: Investment and Underwriters - The entry of cornerstone investors, including Anke Biotechnology Hong Kong, DC Alpha SPC, and Guotai Junan Securities, has been confirmed, with a total investment amounting to HKD 200 million [1] - CITIC Securities and Haitong International are acting as joint sponsors for the offering [1]
新股消息 宝济药业-B(02659)招股结束 孖展认购额录得2692.1亿港元 超购2690.8倍